financetom
Business
financetom
/
Business
/
Masimo smartwatches infringe Apple design patents, US jury says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo smartwatches infringe Apple design patents, US jury says
Nov 3, 2024 12:04 PM

Oct 25 (Reuters) - Apple ( AAPL ) convinced a federal

jury on Friday that health monitoring tech company Masimo's ( MASI )

smartwatches infringe two of its design patents.

The jury, in Delaware, agreed with Apple ( AAPL ) that Masimo's ( MASI ) W1

and Freedom watches and chargers willfully violated Apple's ( AAPL )

patent rights in smartwatch designs, awarding the tech giant

$250 in damages. Apple's ( AAPL ) attorneys told the court the "ultimate

purpose" of its lawsuit was to win an injunction against sales

of Masimo's ( MASI ) smartwatches after an infringement ruling.

The jury also determined that Masimo's ( MASI ) watches did not

infringe Apple ( AAPL ) patents covering smartwatch inventions that the

tech giant had accused Masimo ( MASI ) of copying.

Masimo ( MASI ) said in a statement that the company appreciated the

jury's verdict "in favor of Masimo ( MASI ) and against Apple ( AAPL ) on nearly

all issues," and that the decision only applied to a

"discontinued module and charger."

"Apple ( AAPL ) primarily sought an injunction against Masimo's ( MASI )

current products, and the jury's verdict is a victory for Masimo ( MASI )

on that issue," Masimo ( MASI ) said.

Apple ( AAPL ) said in a statement that it was "glad the jury's

decision today will protect the innovations we advance on behalf

of our customers."

Irvine, California-based Masimo ( MASI ) accused Apple ( AAPL ) of hiring

away its employees and stealing its pulse oximetry technology

after discussing a potential collaboration. Masimo ( MASI ) convinced the

U.S. International Trade Commission last year to block imports

of Apple's ( AAPL ) Series 9 and Ultra 2 smartwatches after the

commission found that their technology for reading blood oxygen

levels infringed Masimo's ( MASI ) patents.

Apple ( AAPL ) has appealed the decision and resumed selling the

watches after removing the technology. The tech giant

countersued Masimo ( MASI ) for patent infringement in 2022, alleging

that Masimo ( MASI ) copied Apple Watch features to use in its

smartwatches.

Apple ( AAPL ) also accused Masimo ( MASI ) of using lawsuits at the ITC

and in California to "make way for Masimo's ( MASI ) own watch." Masimo ( MASI )

said Apple's ( AAPL ) patent lawsuit was "retaliatory" and "an attempt to

avoid the court in which the parties have been litigating their

dispute."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Chevron Cabinda Gulf Operations Resume After Release of Oil
Update: Chevron Cabinda Gulf Operations Resume After Release of Oil
Jan 28, 2025
04:58 AM EST, 01/28/2025 (MT Newswires) -- (Updates with attribution to Chevron ( CVX ) throughout and additional information in the last two paragraphs.) Chevron ( CVX ) said its Cabinda Gulf Oil operations in Angola have resumed normal operations after an oil sheen and debris were found nearby along the Atlantic Ocean coastline. About five barrels of oil were...
AstraZeneca, Daiichi Sankyo's Enhertu Gets US FDA Approval for Treatment of Inoperable Breast Cancers
AstraZeneca, Daiichi Sankyo's Enhertu Gets US FDA Approval for Treatment of Inoperable Breast Cancers
Jan 28, 2025
04:57 AM EST, 01/28/2025 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said their drug Enhertu has been approved in the US for the treatment of adult patients with certain types of inoperable breast cancer that has progressed on one or more endocrine therapies. The drug, also known as fam-trastuzumab deruxtecan-nxki, has specifically been approved for use in...
Drugs Made In America Acquisition Prices $200 Million IPO
Drugs Made In America Acquisition Prices $200 Million IPO
Jan 28, 2025
04:49 AM EST, 01/28/2025 (MT Newswires) -- Drugs Made In America Acquisition (DMAA) said late Monday it priced an initial public offering of 20 million units at $10 each. The company granted the underwriter a 45-day option to purchase up to an additional 3 million units. Each unit consists of one ordinary share and one right to receive one-eighth of...
Fundstrat's Tom Lee Sees Nvidia's 17% Plunge As An 'Opportunity,' Calls Nasdaq's Over 600 Points Plunge Drop A Market 'Overreaction'
Fundstrat's Tom Lee Sees Nvidia's 17% Plunge As An 'Opportunity,' Calls Nasdaq's Over 600 Points Plunge Drop A Market 'Overreaction'
Jan 28, 2025
Fundstrat Global Advisors‘ head of research Tom Lee believes Monday’s massive tech sector sell-off, which saw Nvidia Corp. ( NVDA ) shares plunge 17%, represents a buying opportunity rather than a fundamental shift in the artificial intelligence landscape. What Happened: “To me, it’s an overreaction,” Lee told CNBC’s “Closing Bell,” comparing the drop to Nvidia’s March 2020 decline that proved...
Copyright 2023-2026 - www.financetom.com All Rights Reserved